News

July 8, 2019

Puma Applies to FDA to Extend Nerlynx’s Use to HER2-Positive Metastatic Breast Cancer

News

Puma Biotechnology is seeking to extend the use of its breast cancer medicine Nerlynx (neratinib), in combination with capecitabine, to treat women with HER2-positive breast cancer whose disease has spread ... Read more

July 3, 2019

CHMP Recommends Tecentriq-Abraxane Combination to Treat Some Triple-negative Breast Cancers in Europe

News

The  Committee for Medicinal Products for Human Use (CHMP),  an arm of the  European Medicines Agency , has recommended the approval of Tecentriq (atezolizumab) in combination with the chemotherapy Abraxane (nab-paclitaxel) as a ... Read more

July 1, 2019July 1, 2019

Fujifilm Bus Hits the Road to Offer Breast Cancer Screenings and Promote Early Diagnosis

News

Fujifilm Medical Systems USA has launched a nationwide effort to enhance access to breast cancer screening and raise awareness about the importance of early disease detection. Called “Aspire to Be ... Read more

June 28, 2019

Breast Cancer Index Identifies Patients Who Will Benefit From Extended Endocrine Therapy, Data Shows

News

Biotheranostics‘ Breast Cancer Index can help distinguish which breast cancer patients will derive a benefit from prolonged endocrine therapy — allowing those who don’t to stop treatment and avoid its ... Read more

June 26, 2019

European Commission Approves Talzenna to Treat Some Breast Cancers

News

The European Commission (EC) has approved Pfizer‘s Talzenna (talazoparib) for the treatment of patients with advanced forms of HER2-negative breast cancer with BRCA mutations who have been treated with chemotherapy ... Read more

June 24, 2019June 27, 2019

Tecentriq-Abraxane Combo Prolonging Survival in TNBC Patients, Phase 3 Trial Data Show

News

Tecentriq in combination with Abraxane, a chemotherapy, continues to prolong overall survival in adults with triple-negative breast cancer (TNBC) who test positive for the PD-L1 factor, a new interim analysis from ... Read more

June 21, 2019

Anti-Diarrheal Medicines Improve Tolerability of Nerlynx in Breast Cancer Patients

News

Severe diarrhea is a side effect experienced by more than one-third of women with HER2-positive early-stage breast cancer receiving secondary treatment with Nerlynx (neratinib). But preventive treatment with loperamide (brand ... Read more

June 19, 2019

Kisqali-Endocrine Therapy Combo Increases Overall Survival In Hormone Receptor-Positive Breast Cancer Patients, Study Shows

News

A combination of endocrine therapy and the targeted therapy Kisqali (ribociclib) is more effective than endocrine therapy alone at prolonging the survival of premenopausal women who have metastatic hormone receptor-positive ... Read more

June 17, 2019

FDA Approves Herceptin Biosimilar Kanjinti for HER2-positive Breast Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Amgen and Allergan’s Kanjinti (trastuzumab-anns), a biosimilar to Genentech’s Herceptin (trastuzumab), for all indications of its reference product — including as a treatment ... Read more

June 14, 2019

Susan G. Komen, Cancer Australia to Co-fund Metastatic BC Research

News

A new partnership between Susan G. Komen and Cancer Australia will grant a researcher $450,000 over three years to study metastatic breast cancer. Through a Career Catalyst Research Grant provided ... Read more